HOME RESEARCH PUBLICATIONS WORKSHOPS FILMS APPS TALKS NEWS STAFF CONTACT ...Go Back

Principal Investigator - Prof Val Jenkins

Co-Investigator - Prof Dame Lesley Fallowfield

Researcher - Lucy Matthews

Data Manager - Shirley May

Funder: Sanofi

QoL, pain and information needs were recorded during treatment for metastatic castrate-resistant prostate cancer (mCRPC) in men from 20 UK cancer centres starting various systemic mCRPC treatments.

132 patients were recruited and completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months. Overall QoL declined significantly by 6 months and many patients reported inadequate pain control. Information needs concerning coping at home and supportive care were not met.

• Current Stage:

  Closed

• Publication

  Patient reported outcomes in metastatic castrate-resistant prostate cancer https://doi.org/10.1038/nrclinonc.2016.100

• Publication

  EXTREQOL identifies ongoing challenges in maximising quality of survival in men with mCRPC https://doi.org/10.1016/j.clon.2018.02.001

• Publication

  Treatment experiences, information needs, pain and quality of life in men with mCRPC: Results from the EXTREQOL study https://doi.org/10.1016/j.clon.2018.11.001

• Publication

  Patients' and their partners' views of care and treatment provided for metastatic castrate resistant prostate cancer in the UK https://doi.org/10.1111/ecc.13140

• Poster

  Survey Results on Managing Metastatic Castrate Resistant Prostate Cancer (mCRPC) posters/Poster for Baun 2017 final version 14.11.17.pdf
Presented at British Association of Urological Nurses (BAUN) conference 2017

• Poster

  Patients' and partners' views of treatment and care provided for metastatic castrate resistant prostate cancer (mCRPC) in the UK posters/135 X 90 ESMO 2018 S CATT.pdf
Presented at European Society for Medical Oncology (ESMO) conference 2018

EMAIL: adminshore-c@sussex.ac.uk PHONE: 01273 873019 TWITTER: https://twitter.com/SussexSHORE_C LOCATION: MAP